Category Archives: Ulcerative Colitis

Ulcers in the Large Intestine | Treatment | Real Testimonial Ulcerative Colitis is a disease that is characterised by inflammation and ulcers in the superficial layers of the large intestine. In Ayurveda, Ulcerative colitis (Rakata Atisaar) is well managed... By: Dr. Vikram Chauhan … Continue reading →

Ulcerative Colitis Treatment by Ayurvedic Medicines - Real Testimonial This is a myth among people that Ulcerative colitis cannot be treated well and prolonged use of allopathic medicines is needed but in Ayurveda there are certain natural medications which completely... By: Dr. Vikram Chauhan … Continue reading →

ginger beer cocktail recipe - healthy drink - good for ulcerative colitis and crohn's disease diet http://youtu.be/AjnB6_3PWEI This is simple recipe for a ginger beer cocktail. if you suffer from colitis or Crohn's disease or if you don not, ginger should be part of your healthy diet. unless... By: You … Continue reading →

Are you aggravating your ulcerative colitis? WEBSITE: http://www.aplacetoheal.webs.com STORE: http://www.aplacetoheal.ecrater.com PHONE CONSULTATIONS: http://www.aplacetoheal.ecrater.com/p/19397848/phone-consultation E-MAIL ... By: A Place To Heal … Continue reading →

NEW YORK, April 13, 2015 /PRNewswire-USNewswire/ -- In an effort to raise support for patients and families dealing with inflammatory bowel diseases (IBD), the Crohn's & Colitis Foundation of America (CCFA) announces three companies partnering with their Take Steps fundraising program who will help raise funds for groundbreaking research for new IBD treatments. "The number of Crohn's and ulcerative colitis patients in this country continues to increase," said President and CEO of the Crohn's & Colitis Foundation of America Richard J. Geswell. "CCFA is committed to raising funds for critical research initiatives that are leading to better treatment options for patients. The ultimate goal is to find cures one day soon, so we are grateful to the companies' who help support us in getting there." Throughout the month of April, supporters can help in three creative ways: Known collectively as inflammatory bowel disease (IBD), Crohn's disease and ulcerative colitis affects nearly 1 in 200 people. They are painful, medically incurable diseases that attack the digestive system. Crohn's disease may attack anywhere along the digestive track, while ulcerative colitis inflames only the large intestine (colon). Symptoms may include abdominal pain, persistent diarrhea, and rectal bleeding, fever and weight loss. Most people … Continue reading →

Ulcerative Colitis Natural Remedies Ulcerative Colitis Natural Remedies. By: Truman Berst … Continue reading →

New Treatment for Ulcerative Colitis - IBD in the News Edward Loftus Jr., M.D., a gastroenterologist at Mayo Clinic, discusses the recent Food and Drug Administration approval of a new treatment for ulcerative colitis. By: Mayo Clinic … Continue reading →

Kenna's Dream Takes Flight Learn more about Kenna here: http://bit.ly/1zmKFde Starting at a young age, Kenna was forced to fight ulcerative colitis, which later led to a leukemia diagnosis. Kenna's wish was to go to... By: TripIt … Continue reading →

Ulcerative colitis (Medical Condition) Symptoms, risk factors and treatments of Ulcerative colitis (Medical Condition) Ulcerative colitis is a form of inflammatory bowel disease This video contains general medical information... By: Medical Condition Information … Continue reading →

Lexington, Massachusetts (ots/PRNewswire) - Shire plc acknowledges the two petitions filed with the U.S. Patent and Trademark Office (USPTO) on April 2nd by Hayman Capital Management regarding LIALDA(R) (mesalamine) and GATTEX(R) (teduglutide [rDNA origin]). The patents listed in the FDA Orange Book for LIALDA and GATTEX protect the innovation and value Shire brings to patients who benefit from these important medicines. Shire will continue to defend vigorously its patents and pursue all legal options available to protect its products. LIALDA remains the only once-daily mesalamine product indicated for both the induction of remission of mild to moderate ulcerative colitis and for the maintenance of remission of ulcerative colitis. LIALDA is protected by the following FDA Orange Book listed patent: U.S. Patent No. 6,773,720, Mesalazine Controlled Release Pharmaceutical Compositions (the "'720 patent"), which expires in 2020. This patent has already withstood a challenge on its validity in the Federal District Court for the Southern District of Florida. There have not been any approvals of generic versions of LIALDA. GATTEX is approved in the United States to treat adults with short bowel syndrome (SBS) who are dependent on parenteral support. GATTEX was awarded Orphan Drug Designation by the FDA in 2012 and … Continue reading →